Corcept Therapeutics (CORT) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
Corcept Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update
May 9, 2019 4:05 PM EDTMENLO PARK, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its financial results for the quarter ended March 31, 2019.
Financial Highlights
Revenue of $64.8 million, a 12 percent increase from first quarter 2018Fully-diluted GAAP net income of $0.15 per share, compared to $0.14 per share in first quarter... More